Market Overview

MorphoSys, Celgene Create Strategic Alliance to Develop MOR202 to Treat Multiple Myeloma and Certain Leukemias

MorphoSys AG and Celgene
(NASDAQ: CELG) today announced an agreement to jointly
develop MOR202 globally and to co-promote MOR202 in Europe. MOR202 is a
fully human monoclonal antibody targeting CD38 to treat patients with
multiple myeloma (MM) and certain leukemias. MOR202 is currently being
evaluated in a phase 1/2a trial in patients with relapsed/refractory
myeloma. MorphoSys and Celgene will collaborate on the development of
MOR202 in multiple myeloma and other indications and share costs on a
1/3:2/3 basis.

Under the terms of the agreement, MorphoSys will receive an upfront
license fee of EUR 70.8 million (US $92 million) and Celgene will invest
EUR 46.2 million

See full press release

Posted-In: News Guidance Contracts Global


Most Popular

Related Articles (CELG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free